Prot #218224: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, ParallelGroup Study to Evaluate the Efficacy and Safety of Belimumab Administered Subcutaneously in Adults with Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

Project: Research project

Project Details

StatusActive
Effective start/end date1/17/24 → 1/17/27

Funding

  • PPD Investigator Services, LLC (Prot #218224 // Prot #218224)
  • GlaxoSmithKline LLC (Prot #218224 // Prot #218224)